The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. / Waldemar, G; Ibsen, H; Strandgaard, S; Andersen, A R; Rasmussen, S; Paulson, O B.
In: American Journal of Hypertension, Vol. 3, No. 6 Pt 1, 06.1990, p. 464-70.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension
AU - Waldemar, G
AU - Ibsen, H
AU - Strandgaard, S
AU - Andersen, A R
AU - Rasmussen, S
AU - Paulson, O B
PY - 1990/6
Y1 - 1990/6
N2 - The effect of the angiotensin converting enzyme (ACE) inhibitor fosinopril sodium on regional cerebral blood flow (rCBF) was investigated in 8 patients with moderate essential hypertension. A constant dose of chlorthalidone (25 mg/day) was given to stimulate the renin angiotensin system, and fosinopril sodium was given in incremental doses (10 to 40 mg/day) with the aim of obtaining a diastolic blood pressure at or below 90 mm Hg. Regional CBF was measured with xenon-133 inhalation tomography. Repetitive measurements were made at the start of treatment and again after 4 to 12 weeks treatment in the resting supine position, and during lower body negative pressure (LBNP) as a substitute for the upright position. Four hours after the first 10 mg dose of fosinopril the mean arterial pressure (MAP) had been reduced from 127 +/- 13 mm Hg to 105 +/- 9 mm Hg (P less than .01) without any significant change in mean CBF (55 +/- 9 mL/(100 g X min) at baseline versus 52 +/- 9 mL/(100 g X min) after fosinopril). After prolonged treatment with chlorthalidone and fosinopril, mean CBF was still unchanged from baseline levels, when measured 4 and 24 h after a single dose of fosinopril, despite a 10% reduction in MAP (P less than .01). LBNP did not lead to any significant change in rCBF. The regional distribution of CBF was normal in all patients throughout the study. We conclude that treatment with fosinopril sodium causes a moderate fall in blood pressure without any adverse effects on rCBF.
AB - The effect of the angiotensin converting enzyme (ACE) inhibitor fosinopril sodium on regional cerebral blood flow (rCBF) was investigated in 8 patients with moderate essential hypertension. A constant dose of chlorthalidone (25 mg/day) was given to stimulate the renin angiotensin system, and fosinopril sodium was given in incremental doses (10 to 40 mg/day) with the aim of obtaining a diastolic blood pressure at or below 90 mm Hg. Regional CBF was measured with xenon-133 inhalation tomography. Repetitive measurements were made at the start of treatment and again after 4 to 12 weeks treatment in the resting supine position, and during lower body negative pressure (LBNP) as a substitute for the upright position. Four hours after the first 10 mg dose of fosinopril the mean arterial pressure (MAP) had been reduced from 127 +/- 13 mm Hg to 105 +/- 9 mm Hg (P less than .01) without any significant change in mean CBF (55 +/- 9 mL/(100 g X min) at baseline versus 52 +/- 9 mL/(100 g X min) after fosinopril). After prolonged treatment with chlorthalidone and fosinopril, mean CBF was still unchanged from baseline levels, when measured 4 and 24 h after a single dose of fosinopril, despite a 10% reduction in MAP (P less than .01). LBNP did not lead to any significant change in rCBF. The regional distribution of CBF was normal in all patients throughout the study. We conclude that treatment with fosinopril sodium causes a moderate fall in blood pressure without any adverse effects on rCBF.
KW - Adult
KW - Aged
KW - Antihypertensive Agents/pharmacology
KW - Blood Pressure/drug effects
KW - Cerebrovascular Circulation/drug effects
KW - Chlorthalidone/pharmacology
KW - Female
KW - Fosinopril
KW - Humans
KW - Hypertension/diagnostic imaging
KW - Lower Body Negative Pressure
KW - Male
KW - Middle Aged
KW - Organophosphorus Compounds/blood
KW - Proline/analogs & derivatives
KW - Rest
KW - Tomography, Emission-Computed, Single-Photon
U2 - 10.1093/ajh/3.6.464
DO - 10.1093/ajh/3.6.464
M3 - Journal article
C2 - 2142429
VL - 3
SP - 464
EP - 470
JO - American Journal of Hypertension
JF - American Journal of Hypertension
SN - 0895-7061
IS - 6 Pt 1
ER -
ID: 275031670